Home
report store
idiopathic pulmonary fibrosis pipeline insight

Idiopathic pulmonary fibrosis - Pipeline Insight, 2026

Published Date : 2026

Pages : 280

Region : Global,

Summary
TOC Table of Content
LOT
Companies
- Sample Request

Idiopathic Pulmonary Fibrosis Pipeline Summary

DelveInsight’s, “Idiopathic Pulmonary Fibrosis Pipeline Insight, 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Idiopathic Pulmonary Fibrosis: Understanding

Idiopathic Pulmonary Fibrosis: Overview

Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia that is found to affect the middle-aged and older adults; and affects lung tissue (alveoli in particular) by either thickening, stiffening, or persistent and progressive scarring (fibrosis) which increases irreversibly over time. If an individual has IPF, scarring affects the air sacs, limiting the amount of oxygen that gets into the blood. With less oxygen in the blood, one can get breathlessness from everyday activities, like walking. This group of lung disorders is also known as ‘Diffuse Parenchymal Lung Diseases,’ which is characterized by a broader umbrella of ‘Interstitial Lung Diseases (IDLs).

Symptoms of Idiopathic Pulmonary Fibrosis vary from person to person. A person may have infrequent Idiopathic Pulmonary Fibrosis attacks or have symptoms only at a certain time such as when exercising or may have symptoms all the time. Symptoms of Idiopathic Pulmonary Fibrosis resemble many respiratory infections. Common symptoms include Shortness of breath, Chest tightness, pain or pressure, Coughing (especially at night), Trouble sleeping caused by shortness of breath, coughing or wheezing, etc.

The heterogeneity in radiological and histopathological appearances, the rate of progression, and treatment response observed in IPF patients suggest that multiple co-activated pathogenic pathways play a major role in the pathogenesis of the disease. These pathways are subject to complex interactions between several endogenous and environmental factors.

Careful evaluation of clinical, laboratory, x-ray data and high resolution computed tomography (HRCT), and at times lung biopsy material to make a confident diagnosis. This is usually done by a respiratory specialist in union with other specialists with an interest in IPF. The diagnosis of IPF relies on the clinician to assimilate and correlate the clinical, laboratory, radiologic, and/or pathologic data. The therapeutic approach of IPF involves both non-pharmacological and pharmacological strategies. The goals of treatment include:

Disease progression, Reducing symptoms, Prevent acute exacerbations, Prolonged survival

Nonpharmacological treatment modalities of IPF include supplemental oxygen therapy, pulmonary rehabilitation, mechanical ventilation, and palliative care services. The pharmacological treatment options include corticosteroids, immunosuppressive/cytotoxic agents (azathioprine, cyclophosphamide), and antifibrotic agents (e.g., colchicine or d-penicillamine) alone or in combination.

"Idiopathic Pulmonary Fibrosis Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Idiopathic Pulmonary Fibrosis pipeline landscape is provided which includes the disease overview and Idiopathic Pulmonary Fibrosis treatment guidelines. The assessment part of the report embraces, in depth Idiopathic Pulmonary Fibrosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Idiopathic Pulmonary Fibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Idiopathic Pulmonary Fibrosis R&D. The therapies under development are focused on novel approaches to treat/improve Idiopathic Pulmonary Fibrosis.

Idiopathic Pulmonary Fibrosis Emerging Drugs Chapters

This segment of the Idiopathic Pulmonary Fibrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Idiopathic Pulmonary Fibrosis Emerging Drugs

BMS-986278: Bristol-Myers Squibb

Admilparant (BMS-986278) is a potential first-in-class, oral, small molecule lysophosphatidic acid receptor 1 (LPA1) antagonist currently being evaluated as a novel antifibrotic treatment for patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Increased LPA levels and activation of LPA1 are involved in the pathogenesis of pulmonary fibrosis. A preclinical in vitro and in vivo study found that antagonizing LPA1 may be beneficial in treating lung injury and fibrosis. Currently, the drug is in the Phase III stage of its development for the treatment of Idiopathic Pulmonary Fibrosis.

ENV-101: Endeavor BioMedicine

ENV-101 (Endeavor BioMedicine) is an investigational small-molecule therapy being developed by Endeavor BioMedicine for fibrotic diseases, particularly idiopathic pulmonary fibrosis (IPF). It is designed to selectively inhibit pathways involved in fibrosis progression, aiming to reduce excessive tissue scarring and preserve lung function. The drug is currently in early clinical development, with studies focused on evaluating its safety, tolerability, and anti-fibrotic activity. Preclinical findings have shown potential to modulate key drivers of fibrosis, supporting its advancement into human trials. Overall, ENV-101 represents a targeted approach that could offer improved disease control compared to existing symptomatic treatments for fibrotic lung disorders. Currently, the drug is in the Phase II stage of its development for the treatment of Idiopathic Pulmonary Fibrosis.

AZD8965: AstraZeneca

AZD8965 (AstraZeneca) is an investigational small-molecule therapy being developed by AstraZeneca for idiopathic pulmonary fibrosis (IPF). It functions as an arginase (ARG1/ARG2) inhibitor, targeting metabolic pathways linked to fibrosis progression. The drug is currently in Phase I clinical development, with ongoing studies evaluating its safety, tolerability, and pharmacokinetics in healthy participants. By modulating arginase activity, AZD8965 aims to reduce fibrotic remodeling and inflammation, representing a novel mechanism compared to existing IPF therapies. If successful, it could provide a new targeted treatment approach for fibrotic lung diseases. Currently, the drug is in the Phase I stage of its development for the treatment of Idiopathic Pulmonary Fibrosis.

Further product details are provided in the report....

Idiopathic Pulmonary Fibrosis: Therapeutic Assessment

This segment of the report provides insights about the different Idiopathic Pulmonary Fibrosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Idiopathic Pulmonary Fibrosis

There are approx. 70+ key companies which are developing the therapies for Idiopathic Pulmonary Fibrosis. The companies which have their Idiopathic Pulmonary Fibrosis drug candidates in the most advanced stage, i.e. Phase III include, Bristol-Myers Squibb.

Phases

DelveInsight’s report covers around 75+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration

Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Idiopathic Pulmonary Fibrosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Idiopathic Pulmonary Fibrosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Idiopathic Pulmonary Fibrosis drugs.

Idiopathic Pulmonary Fibrosis Report Insights

Idiopathic Pulmonary Fibrosis Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Idiopathic Pulmonary Fibrosis Report Assessment

Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
How many companies are developing Idiopathic Pulmonary Fibrosis drugs?
How many Idiopathic Pulmonary Fibrosis drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Idiopathic Pulmonary Fibrosis?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Idiopathic Pulmonary Fibrosis therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Idiopathic Pulmonary Fibrosis and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players